Aging Companies
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGHIJKLMNOPQRSUVWXYZAAABACADAEAFAGAH
1
(How to Use This Table)is it aging?operating statusshort summary (intended to be objective, usually from company material, edited for brevity)clinical stage (and pipeline)therapy or diagnosticcategory(-ies)hallmark(s)SENS area(s)diseases / indicationsclinical trialsmodalitiesregulatory categoryteam/principals (esp. scientific)(scientific) advisorscontact infogeo(s)public?ticker (Yahoo)market cap (M)employees (publics, Y!)employees (LinkedIn)year foundedprivate funding stagenotable investorstotal raised ($M)other relationslead product(s)publicationspatentsdate updatedadd date if >Oct'19other notes
2
5 Alarm Bioyesoperatingdrugs to boost natural cell defenses against damaging chemicals that arise naturally & accumulate w/ agepre-clinicaltherapysmall moleculespharmaceuticalWilliam BainsAubrey de Grey, Joao Pedro de Magalhaeswilliam@fivealarmbio.comCambridge, UKno2016FAB0018/28/19
3
712 North Incyesoperatingmitochondria modulators for age-related diseasespre-clinicaltherapymitochondriamitochondriaMitoSENSAD, cancer, glaucoma, CVD, unspecificed orphan pediatric diseasepharmaceuticalMarcel AlaviSan Franciscono22016QB39/4/19
4
Aeovian (formerly Aeonian)yesoperatingselective mTORC1 inhibitionpre-clinicaltherapymetabolic / mTORnutri-sensesmall moleculepharmaceuticalStelios Tzannis, Curtis Scribner
Ian Massey, David Lowe, Dudley Lamming, Mustafa Sahin, Jacqueline French
formSan Franciscono32012raised AApollo, venBio, Sofinnova37AE116paper10/8/19
5
Age LabsyesoperatingML on methylation data mortality clock from longitudinal (45yrs) data, for improved clinical trialspre-commercialdiagnosticbiomarkers / methylome clockepigeneticblood testunregulated testEspen Riskedal, Arne Soraas, Karl KallebergOslo, Norwayno22017Norway9/4/19
6
AgeCurve LimitedyesoperatingDTC proteomics from saliva covering 4 of 9 hallmarks, using mass spec & MLcommercialdiagnosticbiomarker / proteomesaliva sampleunregulated testAttila CsordasCambridge, UKno22015raised seed9/21/19Commercial launched in UK. Pilot status in US.
7
AgeX Therapeuticsyesoperatingallogeneic stem cells w/ tech for stable engraftment & low immunogenicity; tissue regeneration drugspre-clinicaltherapystem-cells, reprogrammingstem-cells, nutri-sense, epigeneticRepleniSENSIHD, T2D, CHF, scarless healingcell therapy, small molucelspharmaceuticalMike West, Aubrey de GreySan FranciscoyesAGE$481292017Juvenescence, Jim Mellon, John Mauldin, KizooJuvenescenceVASC1, BAT1, iTR1547, Renelon9/18/19
8
Alectoronly brainoperatingtrigger immune system to cure dementias w/ leads based on GWASph.2 trialstherapy, diagnosticAD, FTD, neuroDs4biologicspharmaceuticalArnon Rosenthal, Robert PaulAdam Boxer, Marco Colonna, Stephen Hauser, Michael Heneka, Lewis Lanier, Liqun Luo, Richard Scheller, Thomas Christian Südhof, Robert Vassar, Berislav ZlokovicSan FranciscoyesALEC$1,3701011042013Orbimed, Polaris, GV, Merck, MBC, AbbVie, AmgenAbbVieAL001, AL101, AL002, AL003many papers9/18/19
9
Alkahestyesoperatingleads from blood proteins that go up or down with age, eg young blood fractions, eotaxin/CCR3 inhibitionph.2 trialstherapyfactorscell-commAD, PD, (wet) AMD7drugs, biologics, blood fractionspharmaceuticalKaroly Nikolich, Steven BraithwaiteTony Wyss-Coray, Jeffrey Cummings, Lennart Mucke, Thomas Rando, Eric Reiman, Lee Rubin, Elia Stupka, Saul VilledaSan Franciscono712014post-seedGrifols, MJFox Found50GrifolsAKST4290, AKST/GRF6019/6021, AKST1210papers9/21/19
10
Altoidaonly brainoperatingaugmented reality & AI mobile app 10min cognitive test, FDA cleared & covered by MedicarecommercialdiagnosticbiomarkerAD, other MCI1mobile appregulated diagnostic (SaMD)Richard Fischer, Ioannis TarnanasWalter Greenleaf, Jon VanLeeuwen, Phil Polakoffcontact@altoida.comHoustonno132016raised AM Ventures, Fyrfly8.3NMI (Neuro Motor Index)peer reviewed paper7/22/19
11
Ambrosiayesdefunct (also see notes)young blood transfusions via self-paid clinical trialclinical trial, phase n/atherapyfactorscell-comm1blood transfusionJesse Karmazin?no20168/4/19
ambrosiaplasma.com & linkedin.com/in/jessekarmazin not up despite claims restarting (bizjournals.com/sanjose/news/2019/06/17/ambrosia-health-young-blood-startup-fda.html). More details: https://www.bloomberg.com/news/articles/2019-02-25/the-bloody-tale-of-ambrosia-the-startup-that-wants-to-slow-aging
12
Ampriononly brainoperatingamplification of misfolded proteins for sensitive detection in CSF & blood, for αS (1st), Aβ, tau
pre-clinical, breakthrough designation
diagnosticproteostasisproteostasisAmyloSENSPD, ADCSF
regulated test or device?
Russ Lebovitz, Claudio Soto, Luis Concha
Info@AmprionMe.com
San Diego, San Francisco
no820079/30/2019Breakthrough device designation from FDA in May 2019 for alpha-Synuclein. Not to be confused with the Germany electrical grid company of the same name.
13
Animal Biosciencesyesoperatinghealthy longevity for pets (primarily dogs, cats, horses)pre-commercialtherapysmall molecules, supplemensveterinaryDoug Korn, Nick SinclairformBostonno6Life BioLife Bio10/8/19
14
Athersys Incyesoperatingallogeneic stem cells for neuro, inflammatory, immune, & CV diseasesph.3 trialstherapystem-cellsstem-cellsRepleniSENSneuroDs, CVD, others9cell therapypharmaceuticalGil Van Bokkelen, John Harrington, William (BJ) Lehmann, Robert (Willie) Mays, Anthony Tinginfo@athersys.comCleveland, OHyesATHX$20675891995MultiStem7/11/19
15
Atropos Therapeuticsyesoperatingdrug platform for modulators of entering senescence, for aging (suppress) & cancer (stimulate) pre-clinicaltherapysenescencesenescencecancer, progeroidDs, undecided agingDssmall molecules?pharmaceuticalTommy Nguyen, Andrew KoffJan Vijg, John Sedivy, William Tap, John Petrini, Oliver Stauchinfo@atroposthera.comSan Franciscono32018QB3some relevant papers8/2/19
16
BioAge Labsyesoperatingdrug discovery platform based on multi-omics on human biobanks w/ 20+yr health records + AIpre-clinicaltherapybiomarker, ?drugspharmaceuticalKristen Fortney, Eric Morgen, Klaus Klumpp, Robert Hughes, Justin Rebo, George Hartman, Elad Gil, Joe Betts-Lacroix, Peter Dilaurainfo@bioagelabs.comSan Franciscono212015closed BFelicis, Andreessen Horowitz, Khosla, AME Cloud, Pear, Redpoint, Caffeinated Captial, Elad Gil347/24/19
17
Biophytisyesoperatingdrug discovery platform for aging based on plant secondary metabolitesph.2 trialstherapysarcopenia, AMD, MD2small moleculespharmaceuticalStanislas Veillet, Rene Lafont, Samuel Agus, Pierre Dilda, Waly DiohJean Mariani, Roger Fielding, Thomas Voit, Jose-Alain Sahel, Ivana KimformParisyesALBPS.PA$330262006Sarconeos (BIO101), Macuneos (BIO201)several papers & posters7/11/19
18
Bioquarkyesoperatingbiologics for regeneration, repair, degenerative diseases w/ leads from regenerative animalsph.1 trialstherapycancer, kidneyDs, neuroDs, brain death1biologics, cell therapypharmaceuticalIra Pastor, Sergei PaylianCalixto Machado, Melisa Cooper, Alejandro Mesples, Nikolai SkibaformPhiladelphia, Tampano102007BQ-Atwo (see bottom)7/28/19
19
BioVivayesoperatingplatform for health tests & treatments (via partners) w/ focus on gene & cell therapies, also counselingcommercialElizabeth Parrish, Jason Williams, Anca Selariu, Mitch Fernandez, David KekichGeorge Church, Bill Zheng, Anders Sandberg, John Schloendorn, Ali Fallah, Aubrey de Grey, Matthew Scholz, Hernando Ramirez LlinasformSeattleno32015Integrated Health Systems8/13/19CEO Parrish underwent out-of-USA gene therapy to extend her telomeres w/ hTERT and for myostatin inhibition then claimed positive results, back when company focus was more directly telomere extension therapy. See also https://en.wikipedia.org/wiki/BioViva
20
BYOMass Therapeuticsyesoperatingcontrol of metabolism for aging / age-related diseasespre-clinicaltherapymetabolismnutri-sensepharmaceuticalMargaret JacksonMassachusettsno12017raised seedJuvenescence6.5Juvenescence7/30/19
21
Calicoyesoperatingbroad mission to improve health and longevity using technology to advance biological sciencetherapypharmaceuticalArthur Levinson, David Botstein, Cynthia Kenyon, Daniel Gottschlingpress@calicolabs.comSan Franciscono1802013raise 2 rounsd from:Google, Abbvie2500
Google, AbbVie
several8/19/19Initially funded/created within Google/Alphabet.
22
CellAgeyesoperating?develop new, more accurate senescent cell measurement based on synthetic promotersresearch, pre-commercialdiagnosticsenescencesenescenceApoptoSENSunregulated testMantas Matjusaitis, Azuolas CiukasAlexandra Stolzing, Juan Carlos AcostaINFO@CELLAGE.ORGGlasgow, Scotlandno22016raised seedKizooCircularis8/2/19Website is .org. Seed raise was 2017 & involved crowdfunding. No mention of total raised. Still only 2 employees? Is this a for-profit company?
23
Celularityyesoperatingallogeneic cell therapies from postpartum human placentas, for cancer & functional regenerationph.2 trialstherapystem-cells, regenerationstem-cellsRepleniSENScancer (solid & blood), otherscell therapypharmaceuticalRobert Hariri, Xiaokui Zhang, Nassir Habboubimedia@celularity.comNew Yorkno1552016Celgene, Bill Maris, Tony Robbins, Human Longevity290CYNK-001thousands8/19/19Also run income generating programs to bank placental stem cells and to treat burns & wounds, with projected $40M revenue.
24
Centers for Age Controlyesoperatingsells AgeMeter multimodal test of biological age (successor to H-SCAN test)commercialdiagnosticbiomarkermultimodal testunregulated testElliot Smallinfo@agemeter.comLas Vegasno12005crowdfundedAgeMeter8/22/19
25
Cerevanceonly brainoperatingdrug discovery platform by analyzing brain cell transcriptome diffs by age, cell type, region, & diseaseph.1 trialstherapyPD, AD, neuroDs3small molecules, mAbspharmaceuticalBrad Margus, Mark Carlton, David Margolin, Lee Dawson, Roland BurliNathaniel Heintz, William Ray, Robert Malenka, James Summers, Jeremy Nathans, Rudolph Tanziinfo@cerevance.comBostonno312016raised ATakeda Pharm, Dementia Discovery Fund, Lightstone26.5CVN424
https://elifesciences.org/articles/37551
7/28/19
26
ChromaDex Corporationyesoperatingnutraceuticals for aging, esp. flagship product Niagen w/ nicotinamide riboside (NR), an NAD+ precursorcommercial, ph.3 trialstherapyNAD+cancer, neuropathy, MCI, aging, obesity, heart failure, mitoDs, peripheral artery diseases, hypertension13nutraceuticalsnutraceuticalRob Fried, Frank Jaksch Jr., Matthew RobertsRoger Kornberg, John Walker, Rudolph Tanzi, Charles Brenner, Rob Beudeker, Bruce Germanmultiple emails & formLos AngelesyesCDXC$222100951999Niagenmany8/5/1913 clinical trials mentioning Chromadex, but fewer sponsored by Chromadex and 23 trials using Niagen (some just not mentioning Chromadex by name).
27
ChronomicsyesoperatingDTC saliva methylation clock, plus software to improve healthcommercialdiagnosticbiomarkers / methylome clocksaliva sampleunregulated testTom Stubbs, Robin Thompson, Daniel HerranzJanet Thornton, Paolo Vineisinfo@chronomics.co.ukLondonno122017raised seedSOSV, Anthemis, RebelBio1.3EpiHealth10/18/19
28
Cleara Biotechyesoperatingsenolytics, initially based on FOXO4-p53 interfering peptidepre-clinicaltherapysenescencesenescenceApoptoSENSpeptide or small molecules?pharmaceuticalPeter De Keizer, Tobias Madl, Marco DemariaBoudewijn BurgeringformNetherlandsno52018raised seedApolloseveral, esp. Cell 20177/11/19
29
CohBar Incyesoperatingfind mtDNA peptides (eg that decrease w/ age) & optimized analogs to treat metabolic dysfunctionph.1 trialstherapymitochondriamitochondriaMitoSENSNASH, obesity, T2D, cancer, other ageDs1peptidespharmaceuticalSteven Engle, Kenneth Cundy, Nir Barzilai, ...Amir Lerman, David Sinclair, Ronald Kahn, James Livingston, Frank Calzoneinfo@cohbar.comSan FranciscoyesCWBR$6911142007CB4211papers & posters10/16/19
30
Continuum Biosciencesyesoperatingdrugs to improve mitochondria health & metabolism (eg to increase metabolism)pre-clinicaltherapymitochondriamitochondria, nutri-senseNASH, obesity, diabetesdrugspharmaceuticalSimon Tucker, Webster Santos, Kyle HoehnJohn Amatruda, David SinclairformBlacksburg, VAno22017raised seedLife Bio0.5Life Bio10/17/19Not to be confused with Continuum Biosciences Consulting: https://www.continuumbiosciences.com/
31
Covalent Bioscienceyesoperatingplatform for catalytic antibodies (w/ advantages over mAbs) 1st for ATTR & Aβ, electrophilic vaccinespre-clinicaltherapy, preventativeproteostasis, targeted eliminationproteostasisAmyloSENSCVD, AD, HIVpharmaceuticalRichard Massey, Sudhir Paul, Stephanie PlanqueRobert Friedland, Joel Buxbaum, Miguel Escobar, Carl Hanson, Seth PincusformHouston, New Yorkno32011several peer reviewed8/3/19
32
Cytegenyesdefunct?exercise mimetic biologics to treat mitochondria dysfunctionpre-clinicaltherapymitochondria, metabolismmitochondriaAD, Parkinson'sbiologicspharmaceuticalGeorge Ugras, Blake HillMilwaukee, WIno22015raised unspecifiedBreakout111/7/19Website found by Google summer/fall 2019 but website did not respond.
33
Daphnia Labsyesoperatingdrug discovery platform via in-vivo phenotypic screens of daphnia water fleas w/ video & ML for anti-agingpre-clinicaltherapylifespan screenspharmaceuticalSarah Constantininfo@daphnia-labs.comSan Franciscono220198/2/19
34
Deciduous Therapeuticsyesoperatingactivate endogenous immune cells to clear senescent cellspre-clinicaltherapysenescencesenescenceApoptoSENSpharmaceuticalSan Franciscono12018QB3, Age17/11/19
35
Denali Therapeuticsonly brainoperatingdrug discovery for neurodegeneration, optimized for brain delivery, guided by genetics & biomarkersph.1 trialstherapyPD, ALS, AD, FTD, MS, neuroDs5small molecules, biologicspharmaceuticalRyan Watts, Carole Ho, Zach SweeneyScott Biller, David Holtzman, Eric Reiman, Kevan Shokat, Henrik Zetterberg, Huda Zoghbi, Marc Tessier-LavigneformSan FranciscoyesDNLI$1,7472302372015DNL201, DNL151, DNL7478/22/19
36
Dorian Therapeuticsyesoperatingblock cellular senescencepre-clinicaltherapysenescencesenescencepharmaceuticalMaddalena Adorno, Benedetta di RobilantformSan Franciscono42018Longevity Fund, YC, BlumbergMBC8/6/19
37
Elevianyesoperatingregulate GDF11 & other circulating factors to restore regenerative capacitypre-clinicaltherapyfactorscell-commCVD, T2D, AD, sarcopeniapharmaceuticalMark Allen, Tony Sandrassagra, Manisha Sinha, Orit Foord, Vongting WangBrock Reeve, Luis Alvarez, Scott Dylla, James Larrickinfo@elevian.comBostonno122017raised seedKizoo, Thynk, Longevity Fund, Bold Capital5.5several8/22/19
38
Elysium Healthyesoperatingnutraceutical Basis to boost NAD+ w/ nicotinamide riboside (NR) & pterostilbene (related to resveratrol)commercial, ph.1 trialstherapyNAD+7nutraceuticalsnutraceuticalEric Marcotulli, Leonard Guarente, Mark Morris25+ inc. George Church, Ana Maria Cuervo, Vera Gorbunova, Jim Kirklandcare@elysiumhealth.comNew Yorkno542014raised BSV Bank, General Catalyst31Basispaper8/8/19
39
Enclear Therapiesonly brainoperatingdevices to access & filter toxic proteins from CSF, 1st for ALSpre-clinicaltherapyproteostasisproteostasisAmyloSENSALS, neuroDsCSF accessdeviceAnthony DePasqua, Kasper Roet, William GormleyKevin Eggan, Clifford Woolf, Manuel Navia, Bernhardt TroutformBostonno62018raised seedThiel Capital, Bioverge, Sanford Biosciences, Presight Capital2LabCentral8/14/19Various company summaries also mention monitoring of CSF.
40
Epimorphy LLCyesoperatingDTC Horvath methylation clockcommercialdiagnosticbiomarkers / methylome clockepigeneticn/ablood test, urine testunregulated testLarry Jiainfo@myDNAge.comLos Angelesno02017Zymo ResearchmyDNAge8/2/19
41
EterlyyesoperatingAI based anti-aging health & fitness monitoring and recs app w/ blockchain coins for incentivesapp launchedrecommendationssoftwareunregulated appAndrew AhachinskyformVancouver, BCno102016raised seedDeep Knowledge VenturesLongevity Token?8/22/19What is the relationship to Longevity Token (LTY) / Longevity United, whose website mentions Eterly as its front-facing app and some team members overlap based on LinkedIn, but CEOs are different, LTY's website doesn't seem to have updates since early 2018, and Eterly website doesn't mention Longevity Token. Are they distinct legal organizations?
42
Eternansyesoperatingsenolytics, peptide (see patent)pre-clinicalsenescencesenescenceApoptoSENSpharmaceuticalYavuz A.formUKno32017patent8/22/19
43
Everon Biosciencesyesdefunct?small molecules & biologics platform based on proprietary aging biomarkers including a frailty index pre-clinicaltherapyAlexander Polinsky, Andrei Gudkov, Olga Chernovainfo@everonbio.comBuffalo, NYno62010several28/22/19News & publications end in 2017.
44
Fauna Biomaybeoperatingcomparative animal genomics & multi-omics for drug discovery to improve human healthpre-clinicaltherapyformSan Franciscono52018raised seedLongevity Fund, True Ventures (lead)4.1Age17/15/19Could go in an aging direction, but appears more committed to the idea of using insights from non-model non-human organisms for human health in general, not necessarily for aging. In favor of an aging categorization: Hibernation is a focus and has relevance for several age-related diseases. Aging is mentioned as a future area of research relevant to hibernation in 1 press article (but as distant future). Investment by Longevity Fund. Conclusion: Wait and see what indications, targets, pathways they go after initially.
45
Fountain Therapeuticsyesoperatingunbiased screening platform for new aging targets using AI, vision, & cellular model of aging hallmarkspre-clinicaltherapyinfo@fountaintx.comSan Franciscono420185QB37/24/19
46
FoxBio / Antoxereneyesoperatingdrug platform using protein manufacturing tech, senolytics targeting p53 pathways (eg p53/FOXO4)pre-clinicaltherapysenescencesenescenceApoptoSENSsmall moleculespharmaceuticalKelsey Moody, Adam Blanden, Cees Wortelinfo@ichortherapeutics.comSyracuse, NYno5raised seedJuvenescence, Kizoo11.5Ichor, Juvenescence8/9/19Ichor spun out Antoxerene. Antoxerene & Juvenescence created FoxBio as a 50-50 joint venture. Considering them (A & FB) as one here for now since FB has no website nor LIn employees.
47
GEn1E Lifesciencesyesoperatingdrug discovery platform for inflammatory & aging diseases; lead is p38α kinase inhibitorpre-clinicaltherapyacute lung injury, agingD?pharmaceuticalRitu Lal, Clint Webb, Wendy LuoDavid Young, Alan Levy, Robert Booth, Leonard HayflickInfo (@) GEn1Elifesci.comSan Franciscono320187/30/19Some profiles on 3rd party sites (older material?) omit mention of aging, instead saying a pipeline for rare diseases. No explanation p38 kinase inhibition's larger role in aging. Giving benefit of doubt for now for putting aging front and center and pledging age-related disease indications coming.
48
Genome Protectionyesoperatingentolimod & other drugs for anti-aging & cancer, esp. by protecting genome, esp. against transposonsph.2 trialstherapytransposonsDNAOncoSENSvarious cancers3small moleculespharmaceuticalAndrei Gudkov, Yakov Kogan, Katerina Andrianovainfo@genomeprotection.comBuffalo, NYno32018seedNorma Investments10.5Everon, Cleveland Biolabsentolimod (drug)several inc. peer-reviewed7/17/19also started with a portfolio of other anti-aging and anti-cancer drugs from parent Everon Biosciences
49
GenSight Biologicsyesoperatingallotopic expression w/ targeting to deliver mRNA to mitochondria, for retinal & neuro mito diseasesph.3 trialstherapymitochondriamitochondriaMitoSENSNA eyeDs, AMD8viral gene therapypharmaceuticalBernard Gilly, Barrett Katz, Harvey MasonsonBotond Roska, Jose-Alain Sahel, Jean Bennett, Ernst Bamberg, Connie Cepko, Serge Picaud, Luk VandebergheParis, NYCyesSIGHT.PA$33316720127/6/19allotopic expression of mtDNA w/ targeting to deliver the mRNA to mitochondria could rescue mito aging; also in pre-clinical development for age-related dementias
50
Gero LLCyesoperatingphysics based data/AI biomarkers f/ blood metabo- & proteo-omes & activity data, as service & appcommercialdiagnostic biomarkerlife insuranceunregulated testPeter Fedichev, Nikolai Kovtunenko, Kristina ZakurdaevaRobert Shmookler, Aubrey de Grey, Dobri Kiprovinfo@gero.aiMoscow, Singaporeno462012several, inc. peer reviewed8/2/19
51
Gerostate Alphayesoperatingpharmaceutical scerening platform to treat agingpre-clinicaltherapylifespan screenspharmaceuticalSimon Melov, Gordon Lithgow, Mark LucanicSMELOV@GEROSTATEALPHA.COMSan Franciscono52018YC, CRCM0.159/12/19
52
Gordian Biotechnologyyesoperatingunbiased, high-throughput, in-vivo screening platform for aging w/ gene therapy & single-cell RNAseqpre-clinicaltherapygene therapypharmaceuticalFrancisco LePort, Martin Borch Jensen, Daniel Fuentes, Chris TowneTom Rando, Randy Platt, David Schaffer, Laura Deming, Edward Lanphier, Thomas Ebelinginfo@gordian.bioSan Franciscono52018Longevity Fund, NJFQB3, Age18/6/19
53
Guided Clarityyesoperatingmitochondria-targeted therapies: trigger apoptosis in cancer, increase mitophagy for agingpre-commercialtherapymitochondriamitochondriaMitoSENScancer, ageDs, neuroDsHelen Chen, Olof MollstedtformSan Franciscono22018SOSV/IndieBio11/7/19
54
Hanako Biotechyesoperatingscreening platfom for oligonucleotide senolytics with high selectivity & senolytic activitypre-clinicaltherapysenescencesenescenceApoptoSENSoligonucleotidespharmaceuticalYuri Shoshan, Noam Pilpel, Amir Bar-Shai, Yossi Ovadya, Dina RaichlinIdo Bacheletinfo@hanako.bioIsraelno1201911/13/1911/13/19
55
Human Rejuvenation Biotechnologiesyesdefunct?clearance of 7-ketocholesterol (a type of lipofuscin) for atherosclerosispre-clinicaltherapyLysoSENSatherosclerosispharmaceuticalcontact@human.bioPhoenix, AZno02014Jason Hope8/9/19Defunct? All the The handful of employeees on LinkedIn say their employment here ended. William Adams' (linked in this cell) says "closure of company".
56
Humanity Incyesstarting?aging-focused health/wellness platform using biomarkers & self-experimentationpre-commercialMichael Geer, Peter WardUKno220198/8/19
57
Ichor Ttherapeuticsyesoperatingbiopharma that spins off subsidiaries inc. senolytics, enzymes for lipofuscin, a CRO, & oral mAb mimeticspre-clinicaltherapyLysoSENSAMD, other undisclosedsmall molecules, biologicspharmaceuticalKelsey Moody, Aaron Wolfe, Cornelis Wortel
info@ichortherapeutics.com
Syracuse, NYno372013raised seedKizoo4.5Antoxerene, FoxBio, LysoClear, Auctus Biologicsseveral8/24/19LysoClear itself doesn't qualify for this list due narrow 1-disease focus, but the platform approach it came from does & lives in Ichor. Auctus could eventually qualify itself w/ similarities to Longevity Biotech, but too little info currently available publicly on indications it will target.
58
InSilico Medicine / GeneraityesoperatingInsilico: AI for drug discovery, biomarkers, & aging. Generait (formerly Juvenescence AI): JV for aging.biomarkersAlex Zhavoronkov, Marine Bozdaganyan, Ivan Ozerov, Jimmy Yen-Chu Lin, Polina MamoshinaCharles Cantor, Michael Levitt, Bud Mishra, Donald Small, Yuri Nikolsky, Kristen Fortney, Alexey Moskalev, Ulrich Muehlnerzhu@insilicomedicine.comHong Kong, Moscowno532014raised BQiming, Wuxi AppTec, Deep Knowledge Ventures, Juvenescence, Bold Capital, Jim Mellon51.3Juvenescencesevenal9/10/19Largely AI for drug discovery (like some other companies not focused on aging) but also consistently focused on aging, publishing on aging, launching aging-focused sites, creating aging-related partnerships, etc. Recent post on Medium suggests shifting focus away from aging. If that happens, Insilico will drop off this list though perhaps Generait might stay if a proper 1st-class company in the sense of others here by then.
59
Integrated Health Systemsyesoperatinggives patients access to gene & cell therapies for anti-aging esp. telomeres & myostatin, BioViva partnercommercialtherapytelomerestelomeresAD, cancer, kidneyDs, aging itselfviral gene therapymedical tourisma team of doctorsinfo@integrated-health-systems.comBritish Virgin Islandsno1BioViva8/14/19Ex-USA travel not mentioned explicitly but apply-for-study link leads to https://mailchi.mp/bioviva-science.com/alzheimers/ which mentions travel to Mexico. Not to be confused with the other Integrated Health System (same exact name) at https://ihs911.com/ which does IT for senior living and related care facilities.
60
Intervene Immuneyesoperatingreverse thymus involution & (immune) aging w/ HGH+DHEA+others; provide thru collaborating physicianscommercial, pre-clinicaltherapyimmuneRepleniSENSGreg Fahy, Bobby Brookeinfo@interveneimmune.comLos Angelesno22011Aging Cell, 2019patent9/12/19TRIIM trial results published in 2019 showed Horvath clock reversal of 2.5yrs over 1yr of study.
61
iuve bioyesoperatingDTC biomarkers of systemic chronic inflammation based on Stanford 1000 immunomes project & AIcommercialdiagnosticbiomarkersblood testunregulated testWolfgang Daum, Zuzana Krejciova-RajaniemiMark Davis, David Furman, Joseph Wuinfo@iuvebio.comSan Franciscono22018Age1iAge8/2/19
62
Juvena Therapeuticsyesoperatingdiscovery platform for proteins promoting tissue regeneration, using proteomics, vision, MLpre-clinicaltherapyfactors, stem-cellsstem-cells, cell-commbiologicspharmaceuticalHanadie Yousef, Jeremy O'ConnellMike Nohaile, David Schaffer, Joe Wu, Peter Jackson, Irina ConboyformSan Franciscono102017raised seedFelicis, Compound, Front Seat, Barney Pell4.3Youssef's patents9/13/19
63
Juvenescenceyesoperatingbiopharma umbrella company that creates/invests-in other companies for aging therapeuticssee portfolio pipelinestherapyGreg Bailey, Declan Doogan, Colin Watts, Alexander Pickett, Margaret Jackson, Nafees MalikAnnalisa Jenkins, Steve Felstead, Howard Federoff, Sef Kurstjens, Charlie Roberts, Jeff Sprouseformno102016raised BForesite, Grok, IPGL, Jim Mellon165several portfolio companies8/26/19
64
Life Biosciencesyesoperatingbiopharma umbrella company that creates/invests-in other companies for aging therapeuticssee portfolio pipelinestherapyMehmood Khan, Tristan Edwards, John Amatruda, Jennifer Cermak, William AveryNir Barzilai, Lindsay Wuinfo@lifebiosciences.comBostonno532017raised B75several portfolio companies8/26/19
65
Life EpigeneticsyesoperatingB2B epigenetic tests as a service (for pharma & nutraceutical clients, research, insurance)commercialdiagnosticbiomarkers / methylome clocklife insurancesaliva sampleunregulated testJon Sabes, Brian Chen, Randy OlsonMichael Curran, Morgan Levine, Raymond McCuley, Andreas Mullerinfo@lifeegx.comMinneapolisno192016subsidiary of GWG Holdings (a public company)GWG Holdings7/30/19Sister company YouSurance (also a subsidiary of GWG) in beta beginning to sell DTC life insurance (using Life Epigenetics service?)
66
LipidEv (Lipid Evolution Ltd.)yesoperatinganti-inflammatory lipids (specialized proresolving mediators) that decline w/ agepre-clinicaltherapyvarious agingDs & inflammatoryDsDerek Clissoldinfo@lipidev.co.ukReading, UKno12014related papers8/2/19
67
Longeveronyesoperatingallogeneic mesenchymal stem cells f/ bone marrowph.2 trialstherapystem-cellsstem-cellsRepleniSENSAF, AD, metabolicDs5cell therapypharmaceuticalGeoff Green, Joshua Hare, Anthony OlivaJeremy Walston, Laura Dugan, Elena Volpi, Hidenori AraiformMiamino122014raised seed78/23/19
68
Longevity Biotechyes, but see notesoperatingplatform peptides long-lived w/ oral administration, 1st or neurodegeneration (via VIP receptors) & T2Dclinical trialstherapyPD, neuroDs, T2D, cancer1peptidespharmaceuticalScott Shandler, Samuel Gellman, Uma sinhaWilliam Degrado, Howard Gendelman, Soumitra Ghosh, Chris Rhodes, James WaschekInfo@LongevityBiotech.comPhiladelphiano62010NMSS, Thiel/Breakout, MJF0.8LBT-3627, LBT-6030several8/23/19Longevity in the name appears to refer to the stability of the peptides, not longevity of the patient. Nonetheless, the platform's early pipeline indications include a variety of age-related diseases, and mostly age-related diseases, even though aging/longevity doesn't seem to be a company mission or criterion, eg based on interview here: https://www.sciwri.club/archives/7375
69
Longevity Bridgeyesoperatingbiomarkers of aging esp. NAD biomarkers, 1st through patient-funded study (also see notes)pre-commercialdiagnosticNAD+blood testsunregulated testMaria Entraigues Abramson, Gary AbramsonGreg Fahy, Aubrey de Grey, Alexandra Stolzig, Michael Rae, Mike Kopemail@longevitybridge.comLos Angelesno220177/30/19LinkedIn company page self description suggests plan for DTC products/services for healthspan/lifespan.
70
LyGenesisyesoperatingregrow organs in one's own lymph nodes, 1st for liver diseases, later thymus, pancreas, & kidneyspre-clinicaltherapyRepleniSENSliverDspharmaceutical?Eric Lagasse, Paulo Fontes, Michael HuffordformPittsburghno32017raised AJuvenescence3Juvenescencea couple papers8/23/19
71
Mesoblastyesoperatingallogeneic mesenchymal stem cells for inflammatory conditionsph.3 trials, approval in Japan & Europetherapystem-cellsstem-cellsRepleniSENSGVHD, HF, chronic back pain, OA, diabetic nephropathy34cell therapypharmaceuticalSilviu Itescu, Fred Grossman, Roger Browninfo@mesoblast.comMelbourneyesMESO$3,34981912004Revascor, Remestemcel-L, MPC-06-IDmanysome info8/23/19A lot of focus on non-age-related conditions, but stem-cell tech clearly applicable to aging too with several aging-related indications. Claimed first allogeneic stem-cell therapy approved in Japan & first in Europe.
72
Methuselah Healthyesoperatingprotein post-translational modification analysis for drug discovery for proteostasispre-clinicaltherapyproteostasisproteostasisAmyloSENSdrugspharmaceuticalDavid Grainger, David Mosedale, Mary Donnellyinfo@methuselah-health.comCambridge, UKno22015Medicxi, Index Ventures11/14/1911/14/19
73
Minovia Therapeuticsyesoperatingautologous stem cells enriched w/ mitochondria to transfer to other cells, for mitochondria dysfunctionph.2 trialstherapymitochondria / mito-transfusion, stem-cellsmitochondriaMitoSENSNA mitoDs, AD, PD, AMD2cell therapypharmaceuticalNatalie Yivgi-Ohana, Noa Sher, Eyal Shoshani, Hadass ReichIsraelno52011https://patents.justia.com/assignee/minovia-therapeutics-ltd7/6/19more details at http://minovia.com/mitochondrial-augmentation-therapy/ & http://minovia.com/open-questions/
74
Mitochondrial Transfusion Inc.yesoperatingextract stem cells, expand & extract youthful mitochondria, transfuse back to bodypre-clinicaltherapymitochondria / mito-transfusionmitochondriaMitoSENSAD, PD, CVD, sarcopenia, other agingDscell/organelle therapypharmaceuticalTom B.San Franciscono120187/10/19
75
Mitoconix Bioonly brainoperatingdrugs for mitochondria health for dementias, 1st by inhibiting pathological mito fissionpre-clinicaltherapymitochondriamitochondriaMitoSENSHD, PD, ADpeptidespharmaceuticalGili Hart, Lior WeissmanDaria Mochly-Rosen, Orian ShirihaiIsraelno102016raised A ('17)FutuRx, Remiges, OrbiMed, Dementia Discovery Fund, Arix Bioscience, RMGP207/7/19lead peptide inhibits Drp1
76
Mitokininonly brainoperatingdevelop neo-substrates that modify kinase activity for mitochondria & neuro diseases, 1st for PDpre-clinicaltherapymitochondriamitochondriaMitoSENSPD, HD, other mito & neuroDs?pharmaceuticalKevan Shokat, Nicholas Hertz, Daniel de LouretM. Flint Beal, X. William Yang, Ray TruantSan Franciscono1020175QB3https://patents.justia.com/assignee/mitokinin-llc7/10/19
77
Mount Tam Biotechnologiesyesoperatingdrug platform for mTOR modulating rapalogs with selective inhibition of mTORC1pre-clinicaltherapymetabolic / mTORnutri-senseLupus, MS, cancer, PD, HDsmall moleculespharmaceuticalRichard Marshak, James StapletonBryan Cox, Jim Stolzenbachjim@mounttambiotech.comBurlington, VTyesMNTM#N/A222014TAM-018/24/19
78
MyndYouonly brainoperatingcognition eval app w/ AI to passively track movement & conversation, platform for therapistscommercialdiagnosticbiomarkerAD, other MCImobile app, telecommunications?Ruth Poliakine Baruchi, Itay Baruchi, formIsraelno112016raised seedAmplifyher, Female Founders Fund, Howard MorganMizuho7/22/19Company webpage indicates more palliative focus than other cognitive testing app companien (eg NeuroTrack, Altoida), but clearly the technology has the potential to be used as cognitive decline biomarker/diagnostic. Being deployed currently as more of a augmentative tool for therapists?
79
Napa Therapeuticsyesoperatingdrug discovery pursuing novel targets related to NAD metabolism using drug discovery AI + NAD sciencepre-clinicaltherapyNAD+small moleculespharmaceuticalEric Verdin (presumably not employee?)no12019Juvenescence3Juvenescence, Insilico Medicine7/31/19
80
Navitor Pharmaceuticalsyesoperatingdrug discovery targeting mTORC1 modulationph.1 trialstherapymetabolic / mTORnutri-sensedepression, HD, MCI, muscle wasting1small moleculespharmaceuticalGeorge Vlasuk, Eddine Saiah, James ("Randy") OwenDavid Sabatini, Michael Hall, Brian Hubbard, Brendan Manning, Mark Murcko3 emailsBostonno242010raised CBrace Pharma, J&J, Sanofi, SR One, Polaris, Longevity Fund78NV-5138several peer reviewed7/31/19
81
NemaLife Inc.yesoperatingautomating C.elegans HTS inc. healthpan/lifespan w/ microfluidics, computer vision, & data intelligencecommercial?toollifespan screenssome specific worm disease modelstool as product, serviceunregulated toolSiva Vanapalli, Mizanur Rahmaninfo@nemalifeinc.comLubbock, TXno42018bioRxiv preprint7/17/19the microfluidics approach distinguishes this from some other worm automation work, eg allowing automated removal of offspring to allow focus on the aging adult worms
82
NeuroTrackonly brainoperatingeye-tracking cognitive (esp. memory) 5min test & multimodal lifestyle digital intervention programcommercial?diagnostic, therapybiomarkerMCI3mobile appregulated? diagnosticElli Kaplan, Nick Bott, Jordan GlennJohn Harrison, Richard Isaacson, Dorene Rentz, Mike Poolesupport@neurotrack.comSan Franciscono432012raised CFounders Fund, Khosla, Marc Benioff, Social Capital, Sozo Ventures50Imprint Memory Assessmenthttps://aging.jmir.org/2018/2/e12031/7/22/19
83
Nuchidoyesoperatingnutraceutical for NAD+ w/o NR, includes regulators of pathways that make/lower NAD+pre-commercialtherapyNAD+nutraceuticalsnutraceuticalNichola ConlonTom KirkwoodNewcastle, UKno52017DeepbridgeTime Capsuleposter8/9/19List of ingredients does not seem to be available yet.
84
Oisin Bio (& OncoSenX)yesoperatingtargeted non-viral gene therapy based on DNA expression, for senescent cells & cancer (via spinout)pre-clinicaltherapysenescencesenescence, DNAApoptoSENS, OncoSENScancer (all solids), more TBDnon-viral gene therapypharmaceuticalMatt Scholz, Gary Hudson, John LewisformSeattleno122014closed seedMethuselah, Kizoo3Entos Pharmaceuticals7/31/19Spun out OncoSenX for cancer (not on this list since devoted only to cancer, but for the purposes of this list the 2 companies are best considered as one).
85
OneSkin Technologiesyesoperatingscreening platform using 3D human skin culture & skin age clock, 1st therapy a topical senolytic peptidepre-clinicaltherapysenescencesenescenceApoptoSENSpeptide for topical useregulated cosmeticCarolina Oliveira, Andres Ochoa, Alessandra Zonari, Mariana Boroniinformation@oneskintech.comSan Franciscono102016raised seedSOSV/IndieBio2.2QB3OS-1, OS-28/2/19
86
OpenCures / OpenOmeyesoperatingDTC multi-omics tests & educationcommercial (limited early access)diagnosticbiomarkerblood test, functional testunregulated testKevin Perrott, Mark Hamalainencontact@opencures.orgSan Franciscono120188/24/19
87
Osiris Greenyesdefunct?DTC aging biomarkers esp. methylation clock, but not accepting new orderscommercialdiagnosticbiomarkers / methylome clockepigeneticblood testunregulated testNeil CopesformTampa, FL?no120167/19/19
88
Oxitope Inc.yesstarting?mAbs for oxidative damage & chronic inflammation by targeting oxidized lipids, for aging diseasespre-clinicaltherapy, diagnostictargeted eliminationCVD, cancer, obesity, metabolicDs, OA, neuroDs, liverDsbiologicspharmaceuticalAlexander Martinez?formSan Diegono12018a few peer reviewed7/19/19
89
Pano Therapeuticsyesstarting?mitochondria drugs for aging & metabolic disorderspre-clinicaltherapymitochondriamitochondriaMitoSENSsmall moleculespharmaceuticalFrancesca FieniSan Franciscono120178/27/19Not to be confused with 2 similarly named bio/pharma companies: Oxford, UK based Panos Therapeutics nor with Pano.com, an SF area biotech/pharma incubator.
90
Pentraxin TherapeuticsyesIP holding companysmall molecule targeting amyloid component for AD & separate CRP inhibition programph.2 trials (Europe)therapyproteostasis, targeted eliminationproteostasisAmyloSENSAD, CVD, neuroDs1 (but old GSK trials of CPHPC also relevant for safety)small moleculespharmaceuticalMark Pepyscontact@pentraxin.comLondonno12001miridesap (formerly CPHPC)several peer reviewed7/19/19
91
PharmatrophiXonly brainoperatingsmall moleculels for neurodegenerative diseases targeting neurotrophin repceptors, esp. p75ph.2 trialstherapyAD, neuroDs1small moleculespharmaceuticalAnne Longo, Frank Longoanne@pharmatrophix.comSan Franciscono22005Dolby11.8LM11A-31several inc. peer reviewed
https://patents.justia.com/assignee/pharmatrophix-inc
7/24/19
92
Ponce de Leon Health / Rejuvantyesoperatingnutriceutical shown to increase lifespan in c.elegans & mammals, key ingredient is alpha-ketoglutaratecommercialtherapynutraceuticalsnutraceuticalTom WeldonRejuvant@webcsr.infono52015raised seedPartisan MngmntRejvant8/9/19Claimed scienc-backed mechanisms of action include blocking SASP and reverting methylation state to be more youthful.
93
Proclara Biosciencesyesoperatingtreat multiple misfolded proteins (Aβ, Tau, α-synuclein, AL, TTR) by targeting the shared amyloid foldph.1 trialstherapyproteostasis, targeted eliminationproteostasisAmyloSENSAD, PD, amyloidosis4biologicspharmaceuticalRichard Fisher, David Michelson, Rajaraman KrishnanPaul Aisen, David Hafler, David Holtzman, Bradley Hyman, Kenneth Marek, Greg Petsko, Beka SolomonformBostonno272007raised EMerieux, Shire, Smedvig110NPT088, NPT189couple papers & posters7/19/19Formerly named NeuroPhage Pharmaceuticals.
94
Prodrome Sciencesyesoperatingmetabolomics for early disease detection & therapy for brain diseases by boosting plasmalogen (a lipid)pre-clinical, commercial (in Canada)diagnostic, therapybiomarker, mitochondria?mitochondria?MitoSENS?PD, neuroDs, cancers, CVD, T2D, liverDs0 but 1 soonnutraceutical?regulated diagnostic, nutraceutical?Dayan Goodenowe, Vijitha SenanayakeIan Wright, John Ryan, Kevin Perrottinfo@prodromesciences.comSaskatoon, Canada; San Diegono72016Prodrome HealthProdromeScanseveral peer reviewed: see both Detect & Cure pages, plus https://www.ncbi.nlm.nih.gov/pubmed/310229597/20/19Diagnostic launched commercially for contract research (https://www.prodromesciences.com/component/content/article/79-blog/98-contract-research-services-launch?Itemid=437) but linked page no longer live. Health clinic operating commercially in Canada (http://prodromehealth.com/).
95
Proteostasis Therapeuticsyesoperatingmodulate protein homeostasisph.2 trialstherapyproteostasisproteostasisAmyloSENScycstic fibrosis, PD, AD7small molecules?pharmaceuticalMeenu Chhabra, Ben Munoz, Geoffrey GilmartinF. Ulrich Hartl, Daniel Finley, Jeffrey Kelly, Randall King, Gregely Lukacs, Richard MorimotoformBostonyesPTI$14248622006PTI-428, PTI-801, PTI-808presentations & papers8/24/19
96
Rejuvenate Bioyesoperatinggene therapy for dogs (eventually humans), 1st for mitral valve diseasepre-veterinary-studytherapyheart & kidney failure, obesity, T2Dgene therapyveterinaryDaniel Oliver, George Church, Noah Davidsohn, Jihyun Kim, Jordan WillisSan Diegono42018seedDigitalis7/19/19
97
Rejuvenation Technologiesyesoperatingextend telomeres via nucleoside-modfied TERT mRNApre-clinicaltherapytelomerestelomeresRNApharmaceuticalJohn Ramunas, Glenn Markov, Helen Blauinfo@rejuvenationtech.com San Franciscono12017paper8/13/19
98
Repair Biotechnologiesyesoperatingreverse atherosclerosis by improving macrophages & rejuvenate the thymus w/ FOXN1pre-clinicaltherapyimmune, gene-therapyLysoSENS, RepleniSENSatherosclerosis, hypercholesterolemia, cancer risk, HIV non-respondersgene therapypharmaceuticalReason, Bill Cherman, Marc Ridilla, Jay MukherjeeRichard Honkanen, Graham Pawelec, David Thomas, Aubrey de Greyinfo@repairbiotechnologies.comSyracuse, NYno32018raised seedJim Mellon, Thynk, Emerging Longevity, SENS2.28/1/19
99
resTORbioyesoperatingselective mTORC1 inhibitorph.3 trialstherapy, preventativemetabolic / mTOR, immunenutri-senserespiratory illness, PD, heart failure, other agingDs1small moleculepharmaceuticalChen Schor, Joan Mannick, Sarb Shergillcontact@restorbio.comBostonyesTORC$4221282016NovartisRTB1018/4/19
100
Retrotopeyesoperatingdeuterium lipids to prevent oxidation, for mitochondria health, for mito & neurodegenerative diseasesph.2-3 trialstherapymitochondriamitochondriaMitoSENSNA mitoDs (FA, INAD), dementias3lipid small moleculespharmaceuticalRobert Molinari, Mikhail Shchepinov, Peter MilnerTom Brenna, Anatoly Buchachenko, Charles Cantor, Amato Giaccia, Aubrey de Grey, Richard Haas, Michael Murphy, David Shima, Jan VijgSan Franciscono172006Timur Artemev22list in white paper7/7/19
Loading...